share_log

Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments

Benzinga Real-time News ·  2021/10/26 12:16
  • Selecta Biosciences Inc (NASDAQ:SELB) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases. 
  • The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies.
  • Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases.
  • Under the terms of the collaboration, Ginkgo is eligible for upfront R&D fees and milestones, including certain milestone payments in Selecta common stock, clinical and commercial milestone payments of up to $85M in cash.
  • Related: Selecta In-Licenses Rights To IgG Protease Platform.
  • Price Action: SELB shares are up 7.24% at $3.83, and DNA shares are up 6.09% at $15.15 during the market session on the last check Tuesday.
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする